Missouri Hemp Trade Association files lawsuit against state’s department of health over ban on psychoactive hemp-derived cannabinoid products
The Missouri Hemp Trade Association has filed a lawsuit in the Cole County Circuit Court seeking to prevent the Missouri DHSS from designating food and beverage products containing psychoactive cannabinoids derived from hemp as adulterated and implementing an embargo.
Photo © iStockphoto.com/KLH49
Following an executive order from Missouri Governor Michael L. Parson, the Missouri Department of Health and Senior Services (DHSS) has begun a policy to “embargo and condemn” “unregulated psychoactive cannabis products.” The order pertains to products that contain “delta-8 tetrahydrocannabinol (THC), delta-10 THC, hexahydrocannabinol (HHC), tetrahydrocannabinol (THC-O), tetrahydrocannabiphoral (THCP), tetrahydrocannabivarin (THCV), and other similar compounds.”
In response, The Missouri Hemp Trade Association has filed a lawsuit in the Cole County Circuit Court seeking declaratory and injunctive relief that prevents the DHSS from designating these foods and beverage adulterated and implementing an embargo. The lawsuit argues that these products are protected by state law because “industrial hemp” is defined separately from “marijuana” which is considered a controlled substance. This is in line with the 2018 Farm Bill, which removed hemp from the list of controlled substances regulated by the Drug Enforcement Agency. According to the plaintiffs, because the cannabinoids cited in the executive order are derived from cannabidiol (CBD) extracted from industrial hemp, they are commodities of industrial hemp and therefore not adulterated. They cites 197.070.02, RSMo, which states that “A food shall not be considered adulterated solely for containing industrial hemp, or an industrial hemp commodity or product.”
The Top 10 Articles from Cannabis Science and Technology in 2024
January 7th 2025It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2024. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
